Postoperative Pain Therapeutics Market Size & Share, by Route of Administration (Oral, Intravenous, Transdermal, Epidural); Drug Type; Drug Class; Therapeutic Use; End user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Postoperative Pain Therapeutics Market - Regional Analysis

North America Market Insights

North America is predicted to capture the largest revenue share of 45.8% in the postoperative pain therapeutics market by the end of 2035. The region’s upliftment in this field is effectively attributed to the high volume of surgical procedures, strong R&D investments, and regulatory push toward safer analgesic alternatives. In August 2025, Johnson & Johnson is expanding its U.S. manufacturing footprint with a USD 2 billion investment in a 160,000+ sq. ft. facility at FUJIFILM’s Holly Springs site in North Carolina, which will support the company's broader plan to manufacture most of its advanced medicines domestically.

The U.S. is augmenting its leadership over the postoperative pain therapeutics market, which represents a major part of the regional revenue. This is effectively propelled by the heightened patient demand for pain relief options that balance efficacy and safety. For instance, in September 2025, AtriCure announced the launch of the cryoXT device, which is a part of its cryoICE platform to address post-operative pain following amputations. The device is U.S. FDA 510(k)-cleared and targets peripheral nerves, making use of cryoablation technology to reduce residual and phantom limb pain.

Canada is vigorously growing in the postoperative pain therapeutics market, primarily fueled by the rising awareness about the risks associated with opioid dependency, as well as by policy and regulatory support for alternative pain management strategies. In March 2022, Heron Therapeutics reported that it received Health Canada approval for ZYNRELEF, which is the first and only extended-release local anesthetic in the country for postoperative pain management, hence encouraging more players to make investments in this field.

U.S. Pharmaceutical Manufacturing Investments Supporting the Postoperative Pain Therapeutics Market (2025)

Source: DCAT

APAC Market Insights

Asia Pacific is recognized as the fastest-growing region in the postoperative pain therapeutics market during the discussed timeframe. The region’s progress in this sector is constantly supported by the rising surgical volumes, expanding healthcare infrastructure, and increasing awareness of pain management options. Besides the investments in anesthesia techniques and the introduction of non-opioid alternatives, they are also readily shaping the clinical preferences across diverse nations. Furthermore, there has been an increased preference from governments and healthcare providers due to enhanced outcomes and reduced hospital stays.

China is considered to be the powerhouse of innovation in the regional postoperative pain therapeutics market, owing to the modernized healthcare system that adopts international standards of care. In June 2025, CSPC Pharmaceutical Group reported that it had received drug registration approval in the country for Meloxicam Injection (III), which is indicated for treating moderate to severe postoperative pain. Besides, the product uses nanocrystal technology to reduce drug particle size, allowing high-dose, intravenous administration with a long-lasting effect of up to 24 hours.

India is also evidently growing in the postoperative pain therapeutics market, effectively propelled by the financial assistance from governing bodies and a greater emphasis on patient comfort and recovery. For instance, in February 2022, Dr. Reddy's Laboratories notified that it had entered into an exclusive sales and distribution agreement with Novartis India Limited for the Voveran, Calcium, and Methergine product ranges in the country, strengthening its portfolio in pain management, hence suitable for steady market growth.

Europe Market Insights

Europe is maintaining a strong position in the postoperative pain therapeutics market owing to the advancements in pain management technologies and increasing awareness among healthcare providers about multimodal analgesia approaches. The prominent countries in the region are proactively adopting innovative drug delivery systems and personalized pain management protocols that remarkably enhance patient outcomes. In this regard, hospitals across this region are integrating non-opioid pain relief methods, such as nerve blocks and regional anesthesia, to enhance recovery after surgery, hence denoting the existence of heightened demand.

Germany has a strong potential in the postoperative pain therapeutics market, effectively driven by a strong focus on clinical research, increasing investments, and the adoption of advanced pain management techniques. In December 2022, Evonik reported that it had invested in Allay Therapeutics, which is developing implants that relieve knee surgery pain for up to three weeks. The company also stated that this technology aims to reduce or eliminate the need for opioid painkillers, promoting faster recovery with fewer side effects.

The U.K. in the postoperative pain therapeutics market is gaining enhanced traction, shaped by national health policies that are encouraging safer opioid prescribing and the promotion of alternative analgesics. In March 2025, the country’s government reported that the MHRA had removed the indication for prolonged-release opioids such as morphine and oxycodone for treating post-operative pain due to risks of persistent opioid use. It also stated that only immediate-release opioids should be prescribed for short-term acute post-surgical pain.

Clinical Developments in Post-Surgical and Acute Pain Management (2021-2025)